AEON logo

AEON AEON Biopharma, Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$0.12
-0.01 (-7.59%)

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, original…

Market Cap: $6.14Mwww.aeonbiopharma.com

Price

No data yet.

Social Signal Score

38
5d
—
30d
35
4 mentions
—
60d
37
6 mentions
—
90d
42
7 mentions
—
news: 7

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 0Sell 0Strong Sell 0

Revenue

$0.00
$0.00
Sep 2022Sep 2026

Analyst Estimates

FY2025
$-0.61
$-0.61–$-0.61
1 analysts
FY2026
$-0.28
$-0.29–$-0.27
2 analysts
FY2027
$-0.19
$-0.20–$-0.17
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert Bancroft
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
0.69
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-51.55
www.aeonbiopharma.com